Introduction: To assess the association of prostate volume index (PVI), defined as the ratio of the central transition zone volume to the peripheral zone volume, and prostatic chronic inflammation (PCI) as predictors of prostate cancer (PCA) risk in patients presenting with normal digital rectal exam and prostate-specific antigen (PSA) ≤10 ng/mL at baseline random biopsies. Methods: We evaluated patients with a negative digital rectal examination (DRE) and a PSA ≤10 ng/mL who underwent initial baseline prostate biopsy from 2010 to 2017. Parameters evaluated included age, PSA, total prostate volume (TPV), PSA density (PSAD), PVI and PCI. All patients underwent 14 core trans-perineal standard biopsies. The association of factors with the risk of PCA was evaluated by logistic regression analysis, utilizing 2 multivariate models: model I included age, TPV, PVI and PCI; model II included age, PSAD, PVI and PC. Results: Overall, 564 Caucasian patients were included. PCA and PCI were detected in 242 (42.9%) and 129 (22.9%) cases respectively. In patients with PCA, the median PVI was 0.83 (interquartile range [IQR] 0.62–1.04). In patients with PCI, the median PVI was 1.12 (IQR 0.81–1.47). In model I, age (OR 1.080) TPV (OR 0.961), PVI (OR 0.517) and PCI (OR 0.249) were associated with PCA risk. In model II, the age (OR 1.074), PSAD (OR 3.080), PVI (OR 0.361) and PCI (OR 0.221) were associated with PCA risk. Conclusions: Higher PVI and PCI predicted decreased PCA risk in patients presenting with normal DRE, and a PSA ≤10ng/mL at baseline random biopsy. In this subset of patients, PVI is able to differentiate patients with PCI or PCA.

Keywords:
Prostate cancer, Prostate volume index, Prostatic chronic inflammation, Prostate biopsy, Prostate-specific antigen, Prostate volume
1.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618–29.
2.
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283–90.
3.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474–9.
4.
Szeliski K, Adamowicz J, Gastecka A, Drewa T, Pokrywczyńska M. Modern urology perspectives on prostate cancer biomarkers. Cent European J Urol. 2018;71(4):420–6.
5.
Porcaro AB, Corsi P, de Luyk N, Sebben M, Tafuri A, Bizzotto L, et al. Prostate volume index stratified prostate cancer risk in patients elected to a first random biopsy set. Tumori. 2017 Jul;103(4):374–9.
6.
Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V, et al. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. Urol Int. 2015;94(3):270–85.
7.
Porcaro AB, Novella G, Cacciamani G, De Marchi D, Corsi P, De Luyk N, et al. Prostate Volume Index Associates with a Decreased Risk of Prostate Cancer: Results of a Large Cohort of Patients Elected to a First Biopsy Set. Urol Int. 2017;98(1):22–7.
8.
Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999 Jul;282(3):236–7.
9.
Porcaro AB, Rubilotta E, Petrozziello A, Ghimenton C, Migliorini F, Zecchini Antoniolli S, et al. Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Arch Ital Urol Androl. 2014 Sep;86(3):208–11.
10.
Porcaro AB, Novella G, Balzarro M, Martignoni G, Brunelli M, Cacciamani G, et al. Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: results of a large cohort study. Asian J Urol. 2015 Oct;2(4):224–32.
11.
Porcaro AB, Novella G, Mattevi D, Bizzotto L, Cacciamani G, Luyk ND, et al. Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy. Curr Urol. 2016 May;9(2):82–92.
12.
Porcaro AB, Novella G, de Luyk N, Corsi P, Cacciamani G, Sebben M, et al. Intraprostatic chronic inflammation is associated with a reduced risk of prostate cancer in patients elected to a first random biopsy set. Tumori. 2017 Sep;103(5):475–82.
13.
Porcaro AB, Mattevi D, Novella G, De Luyk N, Corsi P, Bizzotto L, et al. Associations of Transitional Zone Volume with Intraprostatic Chronic Inflammation and Prostate Cancer Risk in Patients Undergoing a First Random Biopsy Set. Curr Urol. 2018 Feb;11(2):85–91.
14.
Porcaro AB, Tafuri A, Novella G, Sebben M, Mariotto A, Inverardi D, et al. Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set. Urol Int. 2018;100(4):456–62.
15.
Vasavada SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, Moreira DM. Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis. J Urol. 2018 May;199(5):1174–81.
16.
Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F, et al. The role of prostatic inflammation in the development and progression of benign and malignant diseases. Curr Opin Urol. 2017 Mar;27(2):99–106.
17.
MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol. 2006 Sep;176(3):1012–6.
18.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244–52.
19.
Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU Int. 2017 Feb;119(2):225–33.
20.
Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian J Androl. 2015 Mar-Apr;17(2):212–6.
21.
Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, et al. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun;36(6):632–8.
22.
Philip J, Manikandan R, Viswanathan P. Prostate cancers in the transition zone: part 2; clinical aspects. BJU Int. 2005 Apr;95(6):909.
23.
Raventós CX, Orsola A, de Torres I, Cecchini L, Trilla E, Planas J, et al. Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores. Urol Int. 2010;84(2):153–8.
24.
Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol. 2012 Apr;30(2):149–55.
25.
Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, et al. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. J Urol. 2013 Jul;190(1):70–6.
26.
Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005 Oct;23(30):7546–54.
27.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology. 1998 Oct;52(4):631–6.
28.
Moreira DM, de O Freitas DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens. Prostate Cancer Prostatic Dis. 2017 Dec;20(4):413–7.
29.
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011 Jul;60(1):106–17.
30.
Sfanos KS, Hempel HA, De Marzo AM. The Role of Inflammation in Prostate Cancer. Inflammation and Cancer. Springer; 2014. pp. 153–81.
31.
De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016 Sep;13(10):613–26.
32.
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009 Dec;69(16):1774–80.
33.
Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2018 Jan;15(1):11–24.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.